Peripheral levels of brain-derived neurotrophic factor and S100B in neuropsychiatric systemic lupus erythematous

Abstract

Background

The aim of this study was to investigate serum S100B and brain-derived neurotrophic factor (BDNF) in systemic lupus erythematous (SLE) patients, with and without neuropsychiatric (NP) manifestation activity.

Methods

We assessed 47 SLE patients and 20 selected healthy individuals. Disease activity was assessed according to the SLE disease activity index (SLEDAI). Serum BDNF and S100B were measured by enzyme-linked immunosorbent assay.

Results

Serum S100B protein was significantly higher in SLE patients. BDNF levels were significantly decreased in active SLE, when compared with inactive SLE, but not when compared with controls. S100B was clearly higher in the NPSLE group, when compared with the non-NPSLE or control groups. Receiver operating characteristic analysis of S100B revealed an area under the curve of 0.706 that discriminated NPSLE patients with peripheral polyneuropathy.

Conclusions

Our findings reinforce the use of serum S100B as a biomarker in SLE, particularly for NPSLE. Moreover, we found a strong association between serum S100B and peripheral neuropathy, indicating a specific utility for this biomarker in SLE that warrants clinical investigation.

Keywords

BDNF neuropsychiatric lupus S100B

Get full access to this article

View all access options for this article.

References

Sciascia

Bertolaccini

Roccatello

Khamashta

Sanna

. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol 2014; 261: 1706–1714.

Joseph

Scolding

. Neurolupus. Pract Neurol 2010; 10: 4–15.

Toledano

Sarbu

Espinosa

Bargallo

Cervera

. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013; 12: 1166–1170.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.

Moraes-Fontes

Lucio

Santos

Campos

Riso

Vaz Riscado

. Neuropsychiatric features of a cohort of patients with systemic lupus erythematosus. ISRN Rheumatol 2012; 2012: 989218–989218.

Fragoso-Loyo

Richaud-Patin

Orozco-Narvaez

et al.

Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1242–1250.

Iikuni

Okamoto

Yoshio

et al.

Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 253–256.

Martinez Valle

Ordi-Ros

Vilardell-Tarres

. [Neuropsyquiatric manifestations in systemic lupus erythematosus]. Med Clin (Barc) 2009; 132: 797–801.

Mak

RCM

Lau

. Clinical implications of neuropsychiatric systemic lupus erythematosus. Adv Psych Treat 2009; 15: 451–458.

10.

Oroszi

Lapteva

Davis

et al.

The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 1330–1335.

11.

Yang

Lin

Zhao

. Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2008; 27: 353–357.

12.

Donato

Sorci

Riuzzi

et al.

S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009; 1793: 1008–1022.

13.

Goncalves

Leite

Nardin

. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008; 41: 755–763.

14.

Portela

Brenol

Walz

et al.

Serum S100B levels in patients with lupus erythematosus: preliminary observation. Clin Diagn Lab Immunol 2002; 9: 164–166.

15.

Fragoso-Loyo

Cabiedes

Atisha-Fregoso

Llorente

Sanchez-Guerrero

. Utility of serum S100B protein for identification of central nervous system involvement in systemic lupus erythematosus. J Rheumatol 2010; 37: 2280–2285.

16.

Lapa

Postal

Sinicato

et al.

S100beta is associated with cognitive impairment in childhood-onset systemic lupus erythematosus patients. Lupus 2017; 26: 478–483.

17.

Marosi

Mattson

. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol Metab 2014; 25: 89–98.

18.

Fernandes

Molendijk

Kohler

et al.

Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med 2015; 13: 289–289.

19.

Ikenouchi

Yoshimura

Ikemura

Utsunomiya

Mitoma

Nakamura

. Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: a case report. Prog Neuropsychopharmacol Biol Psych 2006; 30: 1359–1363.

20.

Nockher

Renz

. Neurotrophins in inflammatory lung diseases: modulators of cell differentiation and neuroimmune interactions. Cytokine Growth Factor Rev 2003; 14: 559–578.

21.

Bayas

Kruse

Moriabadi

et al.

Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells. Neurosci Lett 2003; 335: 155–158.

22.

Schuhmann

Dietrich

Sel

et al.

A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol 2005; 163: 15–23.

23.

Steiner

Marquardt

Pauls

et al.

Human CD8(+) T cells and NK cells express and secrete S100B upon stimulation. Brain Behav Immun 2011; 25: 1233–1241.

24.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

25.

Gladman

Ibanez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

26.

Olsen

Choi

Fritzler

. Emerging technologies in autoantibody testing for rheumatic diseases. Arthritis Res Ther 2017; 19: 172–172.

27.

Jeong

Hwang

Roh

et al.

Evaluation of an automated screening assay, compared to indirect immunofluorescence, an extractable nuclear antigen assay, and a line immunoassay in a large cohort of Asian patients with antinuclear antibody-associated rheumatoid diseases: a multicenter retrospective study. J Immunol Res 2018; 2018: 9094217–9094217.

28.

Leite

Galland

Brolese

et al.

A simple, sensitive and widely applicable ELISA for S100B: methodological features of the measurement of this glial protein. J Neurosci Method 2008; 169: 93–99.

29.

Jeltsch-David

Muller

. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol 2014; 10: 579–596.

30.

Sciascia

Bertolaccini

Baldovino

Roccatello

Khamashta

Sanna

. Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmun Rev 2013; 12: 426–429.

31.

Schenatto

Xavier

Bredemeier

et al.

Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 829–831.

32.

Ikenouchi-Sugita

Yoshimura

Okamoto

et al.

Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus. World J Biol Psych 2010; 11: 121–128.

33.

Fauchais

Lise

Marget

et al.

Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study. PLoS One 2013; 8: e79414–e79414.

34.

Tamashiro

Oliveira

et al.

Participation of the neutrophin brain-derived neurotrophic factor in neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53: 2182–2190.

35.

Begni

Riva

Cattaneo

. Cellular and molecular mechanisms of the brain-derived neurotrophic factor in physiological and pathological conditions. Clin Sci (Lond) 2017; 131: 123–138.

36.

Mondelli

Cattaneo

Murri

et al.

Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psych 2011; 72: 1677–1684.

37.

Merrill

Buyon

. The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol 2005; 19: 709–726.

38.

Jasmin

Sockalingam

Shahrizaila

Cheah

Zain

Goh

. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide. Lupus 2012; 21: 1119–1123.

39.

Petri

Orbai

Alarcon

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

40.

Florica

Aghdassi

Gladman

Urowitz

Fortin

. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2011; 41: 203–211.

41.

Goncalves

Leite

Guerra

. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psych Neurol 2010; 2010: 790431–790431.

42.

Juranek

Aleshin

Rattigan

et al.

Morphological changes and immunohistochemical expression of RAGE and its ligands in the sciatic nerve of hyperglycemic pig (Sus scrofa). Biochem Insights 2010; 2010: 47–59.

43.

Sbai

Devi

Melone

et al.

RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. J Cell Sci 2010; 123: 4332–4339.

44.

Serra-Millas

. Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J Psych 2016; 6: 84–101.

45.

Spirin

Bulanova

Pizova

Shilkina

. Peripheral nervous system lesion syndromes and the mechanisms of their formation in connective tissue diseases. Neurosci Behav Physiol 2007; 37: 1–6.

46.

Oomatia

Fang

Petri

Birnbaum

. Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol 2014; 66: 1000–1009.

47.

Campello

Almarcegui

Velilla

Hortells

Oliveros

. [Peripheral neuropathy in systemic lupus erythematosus]. Rev Neurol 2001; 33: 27–30.

48.

McNicholl

Glynn

Mongey

Hutchinson

Bresnihan

. A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 1994; 21: 1061–1066.

49.

Wang

. Systemic lupus erythematosus with acute inflammatory demyelinating polyneuropathy: a case report and review of the literature. J Clin Med Res 2016; 8: 555–559.

50.

Villalta

Bizzaro

Bassi

et al.

Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One 2013; 8: e71458–e71458.

51.

Pisetsky

. Anti-DNA antibodies–quintessential biomarkers of SLE. Nat Rev Rheumatol 2016; 12: 102–110.

52.

Gheita

Abaza

Hammam

Mohamed

AAA

II Eissa

. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies. Lupus 2018; 27: 1081–1087.

53.

Guerra

Tortorelli

Galland

et al.

Lipopolysaccharide modulates astrocytic S100B secretion: a study in cerebrospinal fluid and astrocyte cultures from rats. J Neuroinflamm 2011; 8: 128–128.

54.

De Souza

Wartchow

Hansen

et al.

Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuropsychopharmacol Biol Psych 2013; 43: 14–22.

55.

Kimura

Takahashi

Tashiro

Terao

. Amyloid beta up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid beta-related neuritic degeneration. J Neurosci Res 2006; 84: 782–789.

56.

Gulati

Jones

Lee

et al.

Altered blood–brain barrier permeability in patients with systemic lupus erythematosus: a novel imaging approach. Arthritis Care Res (Hoboken) 2017; 69: 299–305.